Home | Welcome to Contract Pharma   
Last Updated Friday, April 18 2014
Print RSS Feed

Breaking News

Related Searches:
May 11, 2010
Anthony G. Busa, Jr., has been named chief executive officer of CEDRA Corp., a division of Worldwide Clinical Trials (WCT) and a provider of Phase I clinical research and bioanalytical services.   Read More »
May 11, 2010
Abbott has entered a licensing and supply agreement with Zydus Cadila of India for a portfolio of pharmaceutical products that Abbott will commercialize in 15 emerging markets.  Read More »
May 11, 2010
JHP Pharmaceuticals sterile manufacturing site based in Rochester, MI successfully completed a GMP/Pre-Approval Audit by the FDA.  Read More »
May 11, 2010
Imperial Innovations, the commercialization arm of Imperial College, has launched IR Pharma Ltd., a new company targeting contract services for the respiratory disease sector of the pharmaceutical industry.  Read More »
May 10, 2010
Genzyme Corp. has initiated a $2 billion stock buyback, under which $1 billion of stock will be repurchased in the near term and financed with debt.  Read More »
May 10, 2010
Evotec AG has entered into a multi-year integrated drug discovery alliance with Genentech to discover novel small molecule therapeutics.  Read More »
May 10, 2010
Hans Thunem has been elected chief executive officer and a board member of Harlan Laboratories, Inc.  Read More »
May 10, 2010
Tekmira Pharmaceuticals Corp. has entered into a multi-year target validation agreement with Bristol-Myers Squibb.   Read More »
May 10, 2010
Takeda Pharmaceutical Co. Ltd. has entered into an agreement with Janssen Pharmaceutical K.K. to co-promote Velcade (bortezomib) for Injection in Japan.  Read More »
May 7, 2010
Bayer HealthCare Pharmaceuticals received approval from the FDA for Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the prevention of pregnancy.  Read More »
May 7, 2010
Meda has acquired exclusive rights to flupirtine for the treatment of fibromyalgia from Adeona Pharmaceuticals, in the U.S., Canada and Japan.  Read More »
May 7, 2010
Aeterna Zentaris Inc. has received orphan drug designation from the FDA for AEZS-108, a doxorubicin targeted conjugate compound for the treatment of ovarian cancer.  Read More »
May 6, 2010
Neil Larimer has been appointed vice president of business development and manufacturing alliances for Akrimax Pharmaceuticals.   Read More »
May 6, 2010
Merck has restructured its co-development and commercialization agreement with Ariad Pharmaceuticals, Inc., obtaining an exclusive license to ridaforolimus, an investigational, oral mTOR inhibitor in development for the treatment of multiple types of can  Read More »
May 5, 2010
Total contract revenue for the quarter was $38.9 million (-10%).   Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On